Recognizing and treating secondary osteoporosis

  title={Recognizing and treating secondary osteoporosis},
  author={Karen Walker-Bone},
  journal={Nature Reviews Rheumatology},
  • K. Walker-Bone
  • Published 1 August 2012
  • Medicine
  • Nature Reviews Rheumatology
Osteoporosis, through its association with fragility fracture, is a major public health problem, costing an estimated $34.8 billion worldwide per annum. With projected demographic changes, the burden looks set to grow. Therefore, the prevention of osteoporosis, as well as its identification and treatment once established, are becoming increasingly important. Osteoporosis is secondary when a drug, disease or deficiency is the underlying cause. Glucocorticoids, hypogonadism, alcohol abuse and… 
Osteoporosis – a current view of pharmacological prevention and treatment
The current and future possibilities for identifying susceptible patients, from fracture risk assessment to shape modeling and in relation to the high heritability of osteoporosis are discussed, and the intimate relationship between the activities of bone forming and bone-resorbing cells is highlighted.
The molecular etiology and treatment of glucocorticoid-induced osteoporosis
The major therapeutic options approved for GIOP treatment include antiresorption drug bisphosphonates, parathyroid hormone N-terminal fragment teriparatide, and the monoclonal antibody denosumab.
Secondary osteoporosis and metabolic bone disease in patients 50 years and older with osteoporosis or with a recent clinical fracture: a clinical perspective
Calcium, phosphate, creatinine, albumin, erythrocyte sedimentation rate in all patients, 24 h urine calcium in men and serum testosterone in men less than 70 years are recommended.
Osteoporosis and malignancy: a dicey combination
A case emphasising that serious underlying illness can present with vertebral fractures and can be missed if other clues from clinical examination and investigations are overlooked is reported.
There is currently limited evidence regarding osteoporosis and osteopenia in premenopausal women, but the use of conservative strategies for co-managing secondary causes may have the potential to improve long-term management of these conditions.
Low bone mineral density in young individuals is associated with greater gingival inflammation and recession
Low BMD in young individuals was associated with greater gingival inflammation and recession when compared to those individuals with normal BMD values, andGingival recession and recession in patients with secondary osteoporosis compared to healthy subjects.
Glucocorticoids and Sarcoidosis: A Longitudinal Study on the Effects on Cortical and Trabecular Bone.
Treatment of initial mild sarcoidosis with dose tapered glucocorticoid therapy only mildly affects the final trabecular and cortical bone and hormone levels.
Non-participation in systematic screening for osteoporosis—the ROSE trial
Barriers to population-based screening for osteoporosis appear to be both psychosocial and physical in nature and measures could include targeted information and reducing physical barriers for attending screening procedures.
Utility of the trabecular bone score (TBS) in secondary osteoporosis
In some situations, like glucocorticoid-induced osteoporosis and in diabetes mellitus, the TBS appears to out-perform DXA, and further research is both needed and warranted to more clearly establish the role of TBS in these and other disorders that adversely affect bone.
Bone Health After Major Upper Gastrointestinal Surgery
Lifestyle changes, vitamin supplementation, drug therapies and regular bone scans can all play a role in preventing deteriorating bone health.


AGA technical review on osteoporosis in gastrointestinal diseases.
Osteoporosis is increasingly recognized as a source of significant disability, an awareness that has prompted clinicians to actively pursue the diagnosis among high-risk patients, and much of the available clinical information regarding osteoporotic screening, outcomes, and therapeutic interventions is derived from the postmenopausal osteoporeosis literature.
Osteoporosis: impact on health and economics
Fracture incidence varies between populations, and is set to increase over coming decades as the global population becomes more elderly, particularly marked in the developing world, which is additionally assuming more-westernized lifestyles that predispose to increased fracture risk.
Osteoporosis in men: the value of laboratory testing
A relatively modest evaluation of men with osteoporosis found many with undiagnosed secondary causes and multiple unrecognized risk factors, including hypogonadism, vitamin D deficiency, hypercalciuria, subclinical hyperthyroidism, and hyperparathyroidism.
Search for hidden secondary causes in postmenopausal women with osteoporosis
Objective: The prevalence of secondary processes in women with postmenopausal osteoporosis (OP) is not well known. The aim of this study was to analyze the prevalence of conditions contributing to
RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
Denosumab, the only RANKL-targeted therapy currently available, increases bone mineral density and decreases fracture rate in men with prostate cancer and is also associated with delayed time to first skeletal-related event and an increase in bone metastasis-free survival in these men.
Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women.
Our purpose in this study was to determine the prevalence of undetected disorders of bone and mineral metabolism in women with osteoporosis and to identify the most useful and cost-efficient
Role of teriparatide in treatment of glucocorticoid-induced osteoporosis
Clinical studies have indicated teriparatide is efficacious in the treatment of GIOP to improve bone mineral density values at the lumbar spine and femoral neck, and some evidence also suggests terIParatide may reduce rates of vertebral fractures in GIOP patients.
Osteoporosis and low bone mass in premenopausal and perimenopausal women.
  • C. A. Moreira Kulak, D. Schussheim, E. Shane
  • Medicine
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2000
Most young women with osteoporosis or low bone mass had estrogen deficiency or another secondary cause of premature bone loss (or both) and a subset of premenopausal and perimenopausal women, however, had no identifiable cause of bone loss.